

University of Vermont Cancer Center  
Investigator-Initiated Therapeutic Trial Incentive (IITTI)  
***\*This opportunity is not current active\****

**Program:** The University of Vermont Cancer Center (UVMCC) will provide support of \$15,000 for therapeutic trial proposals for up to 2 investigators. These funds will support regulatory, data management and clinical research coordination through the UVMCC Clinical Trials Office.

**Rationale:** UVMCC seeks to promote the development of investigator-initiated cancer-focused therapeutic clinical trials in order to provide the best opportunities for patients with cancer. Academic development and assistance of clinician investigators supports this goal<sup>1</sup>.

**Eligibility:** Faculty level (assistant, associate or full professor) UVM Cancer Center members who have UVM Medical Center medical staff privileges are eligible to apply.

**Support:** Successful candidates will be awarded \$15,000 to cover UVMCC Clinical Trials Office costs associated with trial implementation and conduct of new therapeutic investigator-initiated trials.

Funds will be available 7/1/24 and should be utilized within 2 years.

**Deliverables:** Successful candidates will be expected to develop and activate one (1) investigator-initiated therapeutic clinical trial during the period of support and support enrollment to this trial. A progress report is due at the completion of the 2-year funding period.

**Timelines:**

Request for Applications (RFA) announcement: March 1, 2024

Proposal due date: April 12, 2024, 5:00pm

Notification of awards: April 26, 2024

Start date of award: July 1, 2024

**Submission guidelines:**

Applications should be submitted to Ed North, Grants Manager, UVMCC, as a single electronic PDF document: [Edward.north@med.uvm.edu](mailto:Edward.north@med.uvm.edu)

Content should include the following:

- All materials should be completed in Arial font, 11 point, with page margins of 1 inch top/bottom/sides
  - File should be titled as: IITTI\_LastName\_FirstName\_Date
- Proposal for an investigator-initiated therapeutic trial – 2 pages
  - Description of proposed trial
  - Indicate how the trials are cancer focused and therapeutic
  - Provide information about target accrual and anticipated timeline for accrual completion.
- NIH style biosketch, with relevant publications and other support (maximum 5 pages)
  - Contact Ed North for assistance with formatting if required
- Signed approval form by Department Chair (and Division Chief if applicable)

Proposals will be evaluated by a committee.

<sup>1</sup> **Holcombe RF**, Verschraegen C, Chapman AE, Gaffney D, Goldberg RM, Mesa RA, Milhem M, Mims MP, Mitchell EP, Mulkerin D, Vijayakumar S. Status of the clinician investigator in America: An essential health care provider driving advances in cancer care. Journal NCCN, 2021;19:122-125.

Please contact Dr. Holcombe for any questions, concerns, or feedback at:

[randall.holcombe@med.uvm.edu](mailto:randall.holcombe@med.uvm.edu)

University of Vermont Cancer Center  
Investigator-Initiated Therapeutic Trial Incentive (IITTI)  
February 2024

DEPARTMENTAL/DIVISIONAL APPROVAL FORM

Chair Name: \_\_\_\_\_

Chair Department: \_\_\_\_\_

Chair Email: \_\_\_\_\_

Division Chief Name: \_\_\_\_\_

Division: \_\_\_\_\_

Division Chief Email: \_\_\_\_\_

Applicant Name: \_\_\_\_\_

I am aware that the above named applicant has applied for support through the University of Vermont Cancer Center Clinical Investigator-Initiated Therapeutic Trial Incentive (IITTI) award. With my signature below I am providing authorization for this application and confirm departmental support for the applicant, if awarded, to the execution of the goals and objectives of this initiative, throughout its duration.

\_\_\_\_\_  
Chair Signature

\_\_\_\_\_  
Date

\_\_\_\_\_  
Chief Signature (if applicable)

\_\_\_\_\_  
Date

***Signed form to be included with application materials.***